Georgia Medicare Home Infusion Therapy 2026 Guide

Georgia Medicare Home Infusion Therapy (HIT) enables beneficiaries to receive IV drug therapy at home rather than in a hospital or outpatient setting. For every Georgia Medicare beneficiary prescribed IV drug therapy that can be safely administered at home, every physician ordering home infusion therapy for infectious diseases, immune disorders, oncology, parenteral nutrition, or heart failure, every Home Infusion Therapy supplier coordinating drug delivery, nursing visits, and patient education, every health system operating home infusion programs, and every Georgia caregiver supporting a family member receiving IV therapy at home, the Medicare HIT services benefit is a foundational coverage pathway. Section 1834(u) of the Social Security Act provides the statutory framework; the 21st Century Cures Act of 2016 established the original benefit; the permanent HIT services benefit was implemented in a subsequent CMS Home Health Prospective Payment System Final Rule following a transitional payment period authorized by the Bipartisan Budget Act of 2018.

This guide explains the federal authorities (Section 1834(u) of the Social Security Act, the 21st Century Cures Act of 2016, the Bipartisan Budget Act of 2018 transitional payment, federal HIT implementing regulations under 42 CFR Part 414), the HIT services definition and scope, the payment categories, the initial and subsequent visit payment structure, the HIT supplier accreditation requirements through ACHC, CHAP, and The Joint Commission, the mandatory quality reporting under the HIT Quality Reporting Program, the plan of care requirements, the nursing and pharmacy service components, the patient and caregiver training requirements, the distinct coverage of HIT professional services versus drugs (Medicare Part B DME and Part D pathways), the common HIT indications, the cost savings versus hospital infusion, the major Georgia HIT suppliers and health-system home infusion programs, the rural Georgia HIT access considerations, and how Georgia Medicare beneficiaries benefit from home-based IV therapy.

By Brevy Care Team · Last verified May 13, 2026

Georgia Medicare Home Infusion Therapy: The Federal Statutory Framework

Section 1834(u) of the Social Security Act

Section 1834(u) of the Social Security Act establishes Medicare coverage of Home Infusion Therapy services as a permanent benefit, addressing coverage and payment for HIT services, the payment amount and methodology, quality reporting requirements, patient assessment, the Qualified Home Infusion Therapy supplier definition, and underlying definitions. Section 1861(iii) defines "home infusion therapy" as the items and services for the provision of home infusion drugs, generally meaning parenteral drugs and biologicals administered intravenously or subcutaneously in the home through a pump that is an item of durable medical equipment. Refer to the Medicare home infusion therapy services coverage page for the consumer-facing rules and to the Federal Register HH PPS Final Rule for the current implementing regulations.

21st Century Cures Act of 2016

The 21st Century Cures Act of 2016 established the Medicare HIT services benefit framework and directed CMS to establish payment categories, payment amounts, supplier qualifications, and quality reporting requirements. The Cures Act recognized that Medicare lacked a coherent payment mechanism for home infusion professional services, even though Medicare Part B covered the drugs and external infusion pumps through DME.

Transitional HIT Payment Period

The Bipartisan Budget Act of 2018 authorized a transitional Home Infusion Therapy services payment period before the permanent benefit became effective. The transitional payment provided interim Medicare payment for HIT services and used existing Medicare claims data to establish per-diem payment rates for HIT services associated with qualifying drugs.

Permanent HIT Services Benefit

The permanent HIT services benefit was implemented in a subsequent CMS Medicare Home Health Prospective Payment System (HH PPS) final rule, which established detailed implementation rules including the payment categories, initial and subsequent visit differentiation, supplier accreditation requirements, plan of care requirements, and quality reporting. Consult the current HH PPS Final Rule on the CMS website for the operative effective date and rulemaking history.

Federal HIT Implementing Regulations

CMS implements the HIT benefit through federal regulations at 42 CFR Part 414 covering general provisions, eligibility, conditions of payment, payment categories, payment adjustment, and quality reporting. Supplier accreditation rules sit in a separate part of the federal regulations. Verify the operative subsection structure against the current eCFR text.

HIT Services Definition and Scope

What HIT Services Cover

The Section 1834(u) HIT services benefit covers the professional services associated with home infusion therapy. Covered services include:

Pharmacy Services:

• Drug compounding and preparation
• Drug delivery to the patient's home
• Pharmacy quality assurance
• Coordination with the prescribing physician
• Drug interaction and adverse event review

Nursing Services:

• Initial home assessment
• Drug administration (when administered by RN rather than self or caregiver-administered)
• Patient education on drug administration technique
• IV access management
• Patient assessment and monitoring during therapy
• Coordination with the prescribing physician

Patient and Caregiver Training:

• Drug administration technique
• Equipment use (pump, IV access devices)
• Recognition of adverse reactions
• Emergency response
• Sterile technique
• Documentation

Monitoring and Coordination:

• Periodic patient assessment
• Adverse event reporting
• Coordination with prescribing physician
• Plan of care updates

What HIT Services Do NOT Cover

The HIT services benefit specifically does NOT cover:

• The drugs themselves (covered separately under Part B DME, Part D, or other pathways)
• External infusion pumps (covered under Part B DME)
• Standard nursing services unrelated to drug administration (potentially covered under the home health benefit if eligible)
• Hospice patients (HIT services not covered after hospice election)
• Inpatient or facility-based infusion (different benefits apply)

The HIT Payment Categories

Payment Category Framework

Section 1834(u)(2) requires payment categories based on drug complexity. CMS rulemaking under 42 CFR 414.1515 groups qualifying drugs by complexity, with separate per-service-day rates for each category. The specific drug-to-category assignments and dollar amounts are updated annually through Medicare physician fee schedule rulemaking; consult the current CMS HIT Services page for the current category drug lists and rate tables.

In general, lower-complexity infusions (such as certain antifungals and antivirals) sit in the lowest-paying category, intermediate-complexity infusions (such as subcutaneous immune globulin) sit in the middle category, and the most complex infusions (such as chemotherapy and complex parenteral nutrition) sit in the highest-paying category.

Initial Versus Subsequent Visit Payment

Each category has differentiated initial visit and subsequent visit rates:

Initial Visit Rate (higher): Reflects the increased work of the first home infusion visit, including initial assessment, IV access setup, comprehensive patient and caregiver training, and care plan establishment.

Subsequent Visit Rate (standard): Reflects ongoing routine visits during a course of HIT therapy, including drug administration, patient assessment, and progress monitoring.

Service Day Definition

Medicare HIT services are paid on a service-day basis. A service day is defined as a day on which a qualifying home infusion drug is administered. Multiple drug administrations on the same calendar day generally count as one service day.

Annual Payment Updates

HIT payment rates are updated annually through the Medicare Physician Fee Schedule rulemaking cycle. Annual adjustments reflect inflation, market basket updates, and other statutory and regulatory factors.

HIT Supplier Accreditation

Section 1834(u)(5) Qualified Supplier Definition

Section 1834(u)(5) defines a "qualified home infusion therapy supplier" as a pharmacy, physician, or other provider of services or supplier licensed by the State in which the entity furnishes home infusion therapy items and services and that:

• Furnishes infusion therapy to individuals with acute or chronic conditions
• Ensures the safe and effective provision and administration of home infusion therapy
• Provides care coordination with health care providers
• Is accredited by an organization designated by the Secretary
• Meets such other requirements as the Secretary determines appropriate

CMS-Approved Accrediting Organizations

CMS has approved accrediting organizations for HIT supplier accreditation. The three commonly used in the HIT space are:

Accreditation Commission for Health Care (ACHC): Comprehensive standards for pharmacy services, nursing services, patient care, and quality management.

Community Health Accreditation Partner (CHAP): Standards focused on community-based health care including HIT.

The Joint Commission: Standards integrated with broader health care accreditation framework.

Confirm the current CMS-approved accrediting organization list (and current contact details) through the CMS HIT Services page before relying on a supplier's accreditation status.

Accreditation Process

HIT supplier accreditation involves:

• Application to a CMS-approved accrediting organization
• Comprehensive standards review (pharmacy practice, nursing services, patient safety, quality management, leadership, infection control, regulatory compliance)
• On-site survey by the accreditation organization
• Standards-based deficiency identification and correction
• Accreditation decision (initial accreditation terms generally span multiple years)
• Ongoing surveillance and re-accreditation

Failure to Maintain Accreditation

A HIT supplier that fails to maintain accreditation cannot bill Medicare for HIT services. Loss of accreditation effectively halts Medicare HIT operations for the affected supplier.

Plan of Care Requirements

Physician-Established Plan of Care

Section 1834(u) and 42 CFR Part 414 Subpart P require a physician-established plan of care for HIT services. The plan must include:

• Qualifying drug identification
• Indication and clinical rationale
• Dose, frequency, route, and duration
• IV access plan
• Monitoring parameters (laboratory, vital signs, symptoms)
• Patient and caregiver training plan
• Coordination with the HIT supplier
• Expected duration of therapy
• Follow-up plan

Plan of Care Review and Updates

The plan of care must be:

• Established before HIT services begin
• Reviewed and updated at appropriate intervals based on clinical course
• Updated for significant changes (drug changes, new symptoms, complications)
• Communicated to all care team members
• Documented in the medical record

Referring Physician Coordination

The referring physician must:

• Establish the medical necessity of home infusion
• Order the qualifying drug and parameters
• Communicate with the HIT supplier
• Receive and review HIT supplier progress reports
• Address adverse events and complications
• Coordinate with other care team members

Quality Reporting Under the HIT QRP

Section 1834(u)(3) Quality Reporting Authority

Section 1834(u)(3) establishes the Home Infusion Therapy Quality Reporting Program (HIT QRP). The HIT QRP requires qualified HIT suppliers to:

• Report specified quality measures to CMS
• Submit data through CMS-established mechanisms
• Comply with reporting periods and deadlines

HIT Quality Measures

CMS has established quality measures for the HIT QRP including:

• Patient experience measures (e.g., satisfaction with home infusion care)
• Adverse event measures (e.g., catheter-related infections)
• Process measures (e.g., plan of care documentation, patient education)
• Outcome measures (e.g., hospitalizations during HIT)

Non-Reporting Penalty

HIT suppliers that fail to report required quality data are subject to a reduction in the annual payment update for the subsequent calendar year. The specific percentage reduction is set by CMS rulemaking; consult the current CMS HIT QRP page for the active penalty figure. The penalty applies to HIT supplier payment rates and is intended to incentivize quality reporting compliance.

Public Reporting

CMS may publicly report HIT quality data, enabling beneficiary choice based on quality performance. Public reporting frameworks for HIT continue to evolve.

Drug Coverage Coordination

The Critical Distinction

The HIT services benefit covers professional services but NOT the drugs themselves. Beneficiaries and providers must understand the distinct drug coverage pathways:

Medicare Part B DME Pathway

The Medicare Part B Durable Medical Equipment (DME) benefit covers external infusion pumps and certain drugs administered through them under specific Local Coverage Determinations (LCDs). Refer to the current external infusion pump LCD on the CMS Medicare Coverage Database for covered drug categories and specific drugs.

The DME-pathway external infusion pump LCD covers home infusion drug categories including:

• IV antibiotics for serious infections
• Antifungals and antivirals
• Chemotherapy
• Inotropic therapy
• Parenteral nutrition
• Immunoglobulin (subcutaneous via specific pump)
• Pain management
• Other categories

The DME pathway covers:

• The external infusion pump (durable medical equipment)
• The drug
• Disposable supplies (tubing, dressing, etc.)
• Pump rental

Medicare Part D Pathway

Medicare Part D covers certain self-administered infusion drugs and oral chemotherapy. Part D coverage applies when the drug does not qualify for Part B DME coverage. Part D drug coverage is subject to plan formulary, prior authorization, and cost-sharing rules.

Coordination With HIT Services

The HIT services benefit complements but is separate from drug coverage:

• HIT services pay for the professional services (Section 1834(u))
• DME or Part D pays for the drugs
• Both pathways must be in place for a complete home infusion episode

Beneficiary Cost-Sharing Implications

Beneficiaries face cost-sharing for both pathways:

• HIT services: Standard Part B 20 percent coinsurance after deductible
• DME drug and pump: Standard Part B 20 percent coinsurance after deductible
• Part D drug: Plan-specific cost-sharing (deductible, copays, coinsurance, catastrophic-phase considerations)

Medicare Advantage and Medigap may modify cost-sharing.

Common HIT Indications

IV Antibiotics

Home IV antibiotic therapy treats serious infections requiring extended IV antibiotic courses:

• Osteomyelitis (multi-week IV therapy typical)
• Endocarditis (multi-week IV therapy typical)
• Cellulitis (when oral antibiotics inadequate)
• Septic arthritis
• Diabetic foot infections
• Surgical site infections
• Other serious infections

Common home IV antibiotics include ceftriaxone, vancomycin, daptomycin, ertapenem, and piperacillin-tazobactam, among others. Specific antibiotic choice, dose, and duration are determined by the prescribing physician based on the infection.

Immunoglobulin Therapy

Immunoglobulin therapy treats primary immunodeficiency and other conditions:

• Primary immunodeficiency (Common Variable Immunodeficiency, X-linked agammaglobulinemia, others)
• Secondary immunodeficiency (post-bone marrow transplant, hematologic malignancies, etc.)
• Autoimmune neurologic conditions (chronic inflammatory demyelinating polyneuropathy, myasthenia gravis)
• Idiopathic thrombocytopenic purpura

Subcutaneous immune globulin (SCIG), including products such as Hizentra, Hyqvia, Xembify, and Cuvitru, is increasingly preferred for home administration. IVIG remains the appropriate choice for certain indications.

Chemotherapy

Selected chemotherapy regimens can be administered at home:

• Continuous infusion 5-FU for certain GI malignancies
• Continuous infusion regimens with portable pumps
• Subcutaneous chemotherapy
• Maintenance chemotherapy in select circumstances

Home chemotherapy requires careful patient selection, specialized HIT supplier capabilities, and oncologist coordination.

Total Parenteral Nutrition

Home TPN supports patients with intestinal failure or severe malabsorption:

• Short bowel syndrome
• Chronic intestinal pseudo-obstruction
• Mesenteric ischemia
• Other malabsorption conditions

Home TPN typically requires lifelong therapy with associated complications management (catheter infections, liver disease, metabolic complications).

Inotropic Therapy

Home inotropic therapy supports advanced heart failure:

• Continuous dobutamine or milrinone infusion
• Bridge to transplant or destination therapy
• Palliative care for end-stage heart failure

Other Indications

Other HIT indications include:

• Pain management (continuous opioid infusion)
• Antifungal therapy (extended courses)
• Antiviral therapy (CMV, others)
• Iron infusion for severe iron deficiency
• Various biologics for autoimmune conditions

Cost Savings and Quality of Life

Cost Comparison: Home Versus Hospital Infusion

Home infusion typically generates substantial cost savings compared to hospital or outpatient facility infusion:

• Hospital infusion: Higher facility fees, accommodation costs, infection risks
• Outpatient infusion center: Facility fees, transportation costs, time costs
• Home infusion: Lower facility component, no transportation, maintained patient routine

Medicare and total payer cost comparisons consistently demonstrate home infusion is more cost-effective for appropriate patients.

Quality of Life Benefits

Beneficiary quality of life advantages of home-based IV therapy:

• Familiar environment and family support
• Avoidance of hospital-acquired infections
• Maintained sleep and routine
• Continued home and family activities
• Reduced transportation burden
• Greater patient autonomy
• Lower disruption to caregivers

Clinical Outcomes

For appropriate indications and patient selection, clinical outcomes with home infusion are equivalent to hospital infusion for many drug categories. Patient selection, supplier expertise, and coordinated care are critical to maintaining quality outcomes.

Beneficiary Cost-Sharing

Standard Part B Cost-Sharing

HIT services are billed under Medicare Part B. Standard cost-sharing applies:

• Part B annual deductible (amount indexed annually; see Medicare.gov for the current figure)
• 20 percent coinsurance after deductible
• No facility fee (services furnished in home)

Combined Cost-Sharing With Drug Coverage

Beneficiaries also face cost-sharing for drug coverage pathways (DME or Part D), creating combined cost-sharing for a complete home infusion episode.

Medicare Advantage and Medigap

Medicare Advantage plans may offer modified cost-sharing for HIT services. Medigap supplemental policies may cover Part B coinsurance. Beneficiaries should review their specific plan documents.

Georgia Medicare Home Infusion Therapy: Suppliers and Local Access

Major Georgia HIT Suppliers

Coram CVS Specialty Infusion: National HIT supplier with Georgia operations. Provides comprehensive HIT services including infusion nursing, pharmacy, and patient education.

Optum Infusion Pharmacy: National HIT supplier (part of UnitedHealth Group) with Georgia operations.

Option Care Health: National HIT supplier with Georgia operations. Comprehensive home infusion services.

Soleo Health, Amerita, and other regional and national HIT suppliers also serve varying parts of Georgia. Beneficiaries can look up current Medicare-enrolled HIT suppliers serving their ZIP code through the Medicare.gov supplier directory.

Major Georgia Health System Home Infusion Programs

Emory at Home: Emory Healthcare's home infusion program serving Atlanta metro and beyond. Integrated with Emory specialty care.

Wellstar HomeCare: Wellstar Health System's home health and home infusion programs across the Wellstar network.

Piedmont Home Infusion: Piedmont Healthcare's home infusion services.

Northside HomeCare: Northside Hospital's home health and home infusion services.

Rural Georgia HIT Access

Rural Georgia HIT access depends on:

• Regional HIT supplier coverage
• Travel distances for nursing visits
• Pharmacy delivery logistics
• Local nursing workforce
• Telehealth integration for follow-up assessments

Rural beneficiaries may face longer HIT supplier response times and limited HIT supplier choices. Major HIT suppliers maintain regional service models attempting to cover rural Georgia.

Coordination With Georgia Pharmacy Regulation

HIT pharmacies must be licensed by the Georgia Board of Pharmacy and meet Georgia pharmacy practice standards. Compounding pharmacies have additional Georgia regulatory requirements.

Georgia Home Care Licensing

Home infusion nursing services intersect with Georgia home care licensing administered by the Georgia Department of Community Health. Specific licensing categories apply depending on services furnished.

Worked Example 1: IV Antibiotic for Osteomyelitis at Home

A 68-year-old Medicare beneficiary in Marietta is hospitalized with osteomyelitis of the foot following a diabetic foot infection. After surgical debridement, his infectious disease physician recommends an extended course of IV ceftriaxone, completed at home.

HIT supplier referral: The hospital case manager arranges discharge with a HIT supplier (Coram CVS Specialty Infusion). The infectious disease physician establishes the plan of care: daily IV ceftriaxone for the prescribed duration, with periodic monitoring labs.

Initial HIT visit: The HIT supplier nurse conducts an initial home visit, assessing the home environment, establishing IV access via PICC line (placed before discharge), educating the patient and caregiver on PICC line care, sterile technique, drug administration, and adverse event recognition. The pharmacy delivers initial drug supply, IV pump, and supplies.

HIT payment: Medicare pays the antibiotic HIT category rate. Initial visit at the higher rate; subsequent daily service days at the standard rate. Drug and pump are covered separately under Medicare Part B DME via LCD L33718.

Subsequent service days: Each day of ceftriaxone administration is a service day. Most days the patient self-administers (or caregiver administers) under HIT supplier guidance; the HIT supplier provides nursing visits as needed for assessment and any issues.

Coordination with referring physician: The HIT supplier coordinates with the infectious disease physician on weekly lab results, clinical progress, and any adverse events.

Beneficiary cost-sharing: Standard Part B 20 percent coinsurance after deductible for both HIT services and DME drug/pump coverage. Substantially less expensive than hospital inpatient or daily outpatient infusion.

Outcome: Successful completion of the IV antibiotic course at home with osteomyelitis resolution.

Worked Example 2: SCIG Immunoglobulin Therapy at Home

A 60-year-old Medicare beneficiary in Atlanta with Common Variable Immunodeficiency requires immunoglobulin therapy. Her immunologist transitions her from monthly IVIG infusions to weekly home subcutaneous immune globulin (SCIG).

SCIG transition: Her immunologist orders Hizentra weekly subcutaneous infusion, dosed based on her body weight and IVIG dose history.

HIT supplier coordination: Optum Infusion Pharmacy provides the SCIG, pump, supplies, and HIT services.

Initial training visit: A HIT nurse conducts an extensive initial training visit teaching the patient self-administration including site selection, infusion technique, pump operation, and adverse event recognition.

Weekly self-administration: After training, the patient self-administers Hizentra weekly. The HIT supplier provides ongoing nursing support as needed (periodic check-ins, troubleshooting, dose adjustments).

HIT payment: Medicare pays the SCIG HIT category rate. Initial visit at the higher rate; subsequent visits at the standard rate. Drug covered separately.

Quality of life benefit: SCIG home therapy offers improved IgG steady-state levels, reduced infusion-related side effects compared to IVIG, and significantly enhanced quality of life through avoidance of monthly clinic infusions.

Beneficiary cost-sharing: Standard Part B 20 percent coinsurance for HIT and DME components.

Worked Example 3: Chemotherapy Infusion in the Home

A 72-year-old Medicare beneficiary in Augusta with metastatic colorectal cancer receives a 5-FU continuous infusion regimen (FOLFOX). Following the initial oxaliplatin infusion in the oncology clinic, he continues 5-FU continuous infusion at home over the prescribed multi-day infusion period.

Oncologist plan of care: The oncologist establishes the FOLFOX regimen including 5-FU continuous infusion via portable pump after the in-clinic oxaliplatin and 5-FU bolus. Specific dosing, infusion duration, and cycle frequency are determined by the oncologist based on current treatment guidelines.

HIT supplier coordination: Coram provides 5-FU, portable pump (CADD-Solis or similar), and HIT services. The patient returns to the clinic for pump disconnection (or the HIT supplier handles disconnection at home).

HIT payment: Medicare pays the chemotherapy HIT category rate. The higher complexity reflects the chemotherapy-specific monitoring and management.

Drug coverage: 5-FU covered under Part B DME via LCD L33718 (the external infusion pump category includes certain chemotherapy).

Cycle pattern: The FOLFOX regimen repeats on a defined schedule. Each cycle includes a HIT service-day pattern.

Coordination with oncologist: The HIT supplier reports each cycle's progress and any adverse events to the oncology team.

Quality of life: Home chemotherapy infusion enables the beneficiary to continue normal activities during the infusion period rather than requiring extended outpatient clinic stays.

Beneficiary cost-sharing: Standard Part B 20 percent coinsurance.

Worked Example 4: TPN Total Parenteral Nutrition Home Program

A 65-year-old Medicare beneficiary in Savannah has short bowel syndrome following extensive bowel resection for mesenteric ischemia. Her gastroenterologist orders chronic home total parenteral nutrition (TPN).

Initial TPN program: After hospital initiation and stabilization, the gastroenterologist orders home TPN: a customized nutrient mixture infused over a fixed period (typically overnight) via central venous access (Hickman catheter).

HIT supplier: A specialty HIT supplier with TPN expertise (e.g., Coram, Option Care, regional specialty) takes the case. TPN requires daily compounding based on the patient's nutritional needs.

Initial home visit: HIT nurse conducts extensive initial training: central line care, sterile technique, pump operation, recognizing infections and metabolic complications, daily weight monitoring, lab monitoring schedule.

Daily service: Each day of TPN administration is a service day. The HIT supplier delivers daily compounded TPN bags. The patient (or caregiver) connects the bag nightly and disconnects in the morning.

Monitoring: Regular labs (BMP, CMP, magnesium, phosphate, triglycerides, liver tests, micronutrients) per gastroenterology orders. Periodic catheter assessment and infection surveillance.

HIT payment: Medicare pays the complex-TPN HIT category rate ongoing.

Drug coverage: TPN components covered under Part B DME via specific LCDs.

Lifelong therapy: Home TPN is typically lifelong for short bowel syndrome. Coordinated care among gastroenterology, nutrition, infectious disease (for line infections), and the HIT supplier is essential.

Beneficiary cost-sharing: Standard Part B 20 percent coinsurance.

Worked Example 5: Coordination With DME Drug Coverage

A 70-year-old Medicare beneficiary in Atlanta requires home IV vancomycin for MRSA bacteremia treatment. Understanding the dual-pathway coverage is essential.

Two separate coverage pathways:

HIT services (Section 1834(u)):

• Professional services
• Nursing visits and patient training
• Pharmacy coordination
• Quality reporting
• Billed by HIT supplier
• Antibiotic category rate

DME drug and pump (Part B DME and LCD L33718):

• Vancomycin drug supply
• External infusion pump
• IV access supplies
• Tubing, dressings, etc.
• Billed by DME supplier (often the same entity as the HIT supplier through dual enrollment)
• Standard Part B coinsurance

Same supplier, two billings: When the HIT supplier is also enrolled as a DME supplier (most major HIT suppliers are), both pathways flow through the same vendor, but they require separate billing pathways and adhere to separate coverage rules.

Beneficiary perspective: The beneficiary sees a single home infusion service but faces standard Part B cost-sharing on both the HIT services component and the DME drug/pump component.

Coordination importance: Physicians, beneficiaries, and HIT/DME suppliers must understand both pathways to ensure complete coverage and avoid gaps.

Worked Example 6: Rural Georgia HIT Supplier Arrangement

A 73-year-old Medicare beneficiary in Telfair County (rural southeast Georgia) is hospitalized in Macon for cellulitis with bacteremia, requiring multiple weeks of IV antibiotics. The hospital case manager arranges HIT for discharge.

HIT supplier coverage: A national HIT supplier (e.g., Coram, Option Care) covers Telfair County through its regional service area. The supplier's regional pharmacy compounds and delivers drugs; regional nursing handles in-home visits.

Initial visit logistics: HIT nurse drives a significant distance from a regional hub to the patient's home for the initial visit and PICC line assessment. Drug supply is delivered separately by courier or FedEx.

Subsequent care: Most subsequent days, the patient self-administers (with caregiver support) without needing nursing presence. The HIT supplier nurse returns weekly for PICC site assessment, lab draws, and clinical evaluation.

Telehealth integration: Some HIT suppliers offer telehealth check-ins between in-person visits, reducing travel burden while maintaining oversight. Telehealth integration with HIT services continues to evolve.

Logistics challenges: Rural HIT service may involve:

• Longer travel times for nurse visits
• Drug delivery logistics
• Limited supplier choice
• Travel cost considerations
• Coordination with rural primary care

Rural HIT value: Despite the logistics challenges, rural HIT enables beneficiaries to receive treatment at home rather than requiring extended stays in distant urban facilities.

Beneficiary cost-sharing: Standard Part B 20 percent coinsurance applies; rural location does not modify Medicare HIT coverage rules.

Best Practices for Georgia Medicare Beneficiaries

1. Ask about home infusion if you face extended IV therapy. Many indications (IV antibiotics, immunoglobulin, parenteral nutrition, chemotherapy) can be administered at home.
2. Understand the dual coverage pathway. HIT services (professional) and drug/pump (DME) are separately covered with separate cost-sharing.
3. Verify your HIT supplier is Medicare-enrolled and accredited. Use the Medicare provider directory or ask for accreditation status.
4. Establish strong communication with the HIT supplier. Know how to reach them around the clock for clinical questions.
5. Complete patient and caregiver training thoroughly. Drug administration safety depends on competent self-administration or caregiver administration.
6. Document blood draws and labs as ordered. Adherence to monitoring schedules is essential for safety.
7. Recognize warning signs. Fever, redness or swelling at IV site, shortness of breath, or severe reaction symptoms warrant immediate medical contact.
8. Coordinate with your referring physician. Keep your physician informed about HIT progress and any concerns.
9. Use Medigap or Medicare Advantage to reduce cost-sharing. Standard Part B 20 percent coinsurance can add up over extended therapy courses.
10. Maintain sterile technique. Catheter-related bloodstream infection is the most serious HIT complication.
11. Plan for travel and disruptions. If you travel during HIT, coordinate with the HIT supplier for drug delivery and nursing support at the destination.
12. Use telehealth check-ins when available. Some HIT suppliers offer telehealth assessments between in-person visits.
13. Document your therapy. Keep a log of drug administration, symptoms, and any issues.
14. Engage your family caregivers. Caregiver involvement supports safe and effective home IV therapy.

Common HIT Issues and Solutions

1. Coverage confusion: Understand the difference between HIT services (Section 1834(u)) and drug/pump (Part B DME). Both must be in place for coverage.
2. Multiple supplier coordination: Some beneficiaries have separate HIT and DME suppliers; coordination is important.
3. Drug delivery logistics: Confirm delivery schedule and emergency drug supply procedures.
4. PICC or central line complications: Promptly report fever, line site issues, or other concerns to the referring physician.
5. Pump alarms or malfunctions: HIT suppliers should provide around-the-clock technical support.
6. Rural service gaps: Major HIT suppliers cover rural Georgia through regional service models, but logistics may be more complex.
7. Insurance coverage questions: Contact 1-800-MEDICARE, Palmetto GBA, GeorgiaCares SHIP, or your Medicare Advantage plan.
8. Hospice election conflict: HIT services are NOT covered for hospice patients; election of hospice changes coverage.
9. Home health overlap: Home health and HIT are distinct benefits; coordination prevents duplication or gaps.
10. Caregiver burden: Some beneficiaries lack family caregiver support; HIT supplier nursing or alternative arrangements may be needed.
11. Cost-sharing burden: Extended HIT can generate substantial cumulative coinsurance; Medigap or Medicare Advantage helps.
12. Adverse event reporting: Promptly report adverse events to both the HIT supplier and the referring physician.
13. Plan of care updates: Significant changes (drug, dose, complications) require plan-of-care updates and physician communication.
14. Discharge transitions: Hospital discharge to HIT requires advance planning by case management.

A few more common questions:

What is the difference between HIT services and home health? Home health (Section 1861(m)) is a comprehensive benefit covering skilled nursing, therapy, and home health aide services for homebound beneficiaries. HIT services (Section 1834(u)) specifically cover home infusion professional services and do not require homebound status. The two benefits can coordinate but are structurally distinct.

What drugs are covered through HIT? Section 1861(iii) defines home infusion drugs as parenteral drugs and biologicals administered intravenously or subcutaneously through an external infusion pump that is durable medical equipment. The specific covered drugs are identified through the current external infusion pump LCD on the CMS Medicare Coverage Database and related coverage policies.

What is the external infusion pump LCD? It is the Local Coverage Determination for External Infusion Pumps, identifying covered drug categories administered through external infusion pumps under Medicare Part B DME. The LCD lists specific drugs and indications eligible for coverage; consult the current LCD on the CMS Medicare Coverage Database.

Are HIT services covered via telehealth? Limited aspects of HIT can integrate telehealth (e.g., follow-up assessments). The HIT services benefit itself is primarily an in-home professional service. Telehealth integration with HIT continues to evolve.

What is the HIT Quality Reporting Program? The HIT QRP, authorized under Section 1834(u), requires qualified HIT suppliers to report quality measures to CMS. Failure to report results in a reduction in the annual payment update for the subsequent year; consult the current CMS HIT QRP page for the specific reduction figure. Public reporting frameworks continue to evolve.

What about hospice patients? Section 1834(u) excludes hospice patients from the HIT services benefit. Hospice election changes Medicare coverage for HIT-related services. Beneficiaries considering hospice should discuss HIT implications with their care team.

What is the patient's role in home infusion? Patients (with caregiver support as needed) typically self-administer drug through trained technique after initial HIT supplier training. The HIT supplier provides ongoing oversight, periodic in-person nursing visits, and around-the-clock support availability.

What about catheter complications? Catheter-related complications (infection, occlusion, displacement) are the most serious HIT risks. Sterile technique, prompt response to warning signs, and clear protocols for emergency assessment are essential. HIT suppliers should provide around-the-clock clinical support.

How much does HIT cost the beneficiary? Standard Part B 20 percent coinsurance after deductible applies for both HIT services and DME drug/pump components. Medicare Advantage and Medigap may reduce cost-sharing. Extended therapy can generate substantial cumulative coinsurance.

Where do beneficiaries get HIT assistance? Resources include 1-800-MEDICARE, Palmetto GBA, GeorgiaCares SHIP, the Medicare Rights Center, the National Home Infusion Association (NHIA), and individual HIT supplier customer service lines.

Brevy: Your Partner in Understanding Home Infusion Coverage

At Brevy (brevy.com), our mission is to provide Georgia families with comprehensive, up-to-date guidance on Medicare, Medicaid, VA benefits, and the broader eldercare landscape. Home Infusion Therapy enables Georgia Medicare beneficiaries to receive IV drug therapy at home rather than in hospitals or outpatient facilities, offering both cost savings and quality of life advantages.

If you or a family member faces extended IV therapy, talk with your physician about home infusion options. Verify your HIT supplier is Medicare-enrolled and accredited. Understand the dual coverage pathway (HIT services plus drug/pump coverage). Engage caregivers in training. Recognize and respond promptly to warning signs. Brevy continuously updates our content to reflect Medicare HIT policy changes, supplier landscape evolution, and emerging home infusion practices.

Find personalized help navigating Medicare Home Infusion Therapy coverage at brevy.com.